Current Opinion in Hematology was launched in 1994. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of hematology is divided into nine sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Editor and the Section Editor for this issue.
SECTION EDITOR
Stephanie Halene
;)
Stephanie Halene
Dr Stephanie Halene is Associate Professor and interim Section Chief of Hematology at Yale University School of Medicine in the Yale Comprehensive Cancer Center and the Department of Internal Medicine. Dr Halene received her doctorate degree from the Eberhardt-Karls University in Tuebingen, Germany. After a residency in Internal Medicine under Professor Dr Lothar Kanz at the University Hospital Eberhardt-Karls-University, Tuebingen, Germany she joined the laboratory of Dr Donald Kohn, MD, at Childrens Hospital Los Angeles and completed 3 years of postdoctoral research in hematopoietic stem cell biology and gene transduction. In 2000 she joined the Yale Internal Medicine Residency Program in the Research track and in 2002 the Yale Hematology Fellowship Program under the leadership of Dr Bernard Forget, MD, PhD. She studied neutrophil biology under Dr Nancy Berliner, MD, and megakaryopoiesis and megakaryoblastic leukemia under Dr Diane Krause, MD, PhD.
In 2010 she joined the faculty of the Section of Hematology in the Department of Internal Medicine and established her own laboratory, studying myelodysplastic syndromes (MDS) and MDS xenotransplantation.
Dr Halene has established the Hematology Tissue Bank and became Assistant Medical Director of the Clinical Research Support Laboratory in Yale Comprehensive Cancer Center.
In 2019 she assumed the role as interim section Chief of Hematology.
Dr Halene's scientific interests focus on hematopoiesis and myelodysplasia (MDS). In collaboration with her Yale colleagues, she has developed a highly successful xenotransplantation model for MDS and advanced our understanding of RNA splicing factor mutations in MDS and RNA modifications in hematopoiesis and leukemia.
